Galera Therapeutics (GRTX)
(Delayed Data from OTC)
$0.08 USD
0.00 (0.00%)
Updated Sep 20, 2024 03:47 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galera Therapeutics, Inc. [GRTX]
Reports for Purchase
Showing records 1 - 20 ( 26 total )
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem Type A Meeting Scheduled With FDA; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem FDA Rejection; Downgrading to Neutral and PT down to $0.30
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem Regulatory Decision Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Avasopasem Approval Decision; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Assigns Priority Review to Avasopasem Submission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem New Drug Application Submitted on Schedule; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem FDA Submission Approaching; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASTRO Presentations Highlight Avasopasem Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem NDA Submission Near-Term; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rucosopasem Demonstrates Safety in GRECO-1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem Regulatory Submission Near-Term; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem Shows Promising Activity in Phase 2a Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AESOP and GRECO-1 Readouts Approaching; 2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem Rises Like a Phoenix; Upgrading to Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Avasopasem Pivotal ROMAN Trial Fails; Downgrading to Neutral Without PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Spotlights Avasopasem Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As Expected, GC4419 Delivered Positive Pilot Trial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Galera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ROMAN Trial Readout Next Quarter; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R